ESMO Congress 2025

While telisotuzumab adizutecan demonstrated early antitumour activity, only modest benefits were seen with VCN-01 added to standard care

Potentially practice-changing data were presented for atezolizumab plus bevacizumab, and camrelizumab plus rivoceranib in hepatocellular carcinoma

Although the phase III investigational study with IO102-IO103 plus pembrolizumab is negative, it offers precious insights to advance research in the field

Longer follow-up from two studies supports neoadjuvant over adjuvant immune checkpoint inhibition in patients with resectable melanoma and clinically or radiologically detectable metastasis, plus useful insights gained from biomarker analyses will help refine treatment strategies

Primary phase III overall survival analysis suggests that the combination therapy may be a potential new option for previously treated patients with or without liver metastases 

The combination, incorporating the novel antibody–drug conjugate, may transform first-line treatment in the setting, but crucial issues need to be addressed

Presidential Symposium presentation provides insights into the role of 177Lu-PSMA-617 in the treatment of hormone-sensitive prostate cancer, with results also presented in castration-resistant disease 

Phase III data show significant survival improvements with the TROP2-directed antibody–drug conjugate after progression on EGFR tyrosine kinase inhibitors

Effective biomarkers and histology-focused enrichment trials are now needed to further improve patient outcomes

Rivoceranib after prior therapy and peri-operative pembrolizumab demonstrates promising efficacy but it is not superior to the current standard therapy